Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching-Wen Huang

Showing results (141-150 of 193) with videos related to

Pageof 20
Sort By:
International Journal of Clinical and Experimental Pathology|May 15, 2015
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patientsHsiang-Lin Tsai, Chih-Hung Lin, Ching-Wen Huang, et al.
Cancer Management and Research|May 2, 2022
Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to <i>UGT1A1</i> Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-OnlyChing-Chun Li, Tsung-Kun Chang, Yen-Cheng Chen, et al.
International Journal of Colorectal Disease|October 25, 2024
Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasisYen-Cheng Chen, Tsung-Kun Chang, Wei-Chih Su, et al.
Nanomedicine (London, England)|April 21, 2025
Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancerChing-Wen Huang, Huang-Ming Hu, Wen-Hung Hsu, et al.
Asian Journal of Surgery|February 24, 2021
Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancerPo-Jung Chen, Wei-Chih Su, Tsung-Kun Chang, et al.
Journal of Agricultural and Food Chemistry|June 4, 2021
Correlations between Urinary Monoethylhexyl Phthalate Concentration in Healthy Individuals, Individuals with Colorectal Adenomas, and Individuals with Colorectal CancerWei-Chih Su, Yi-Chen Tsai, Tsung-Kun Chang, et al.
Oncology Letters|September 23, 2020
ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiationMing-Yii Huang, Hsin-Hua Lee, Ching-Wen Huang, et al.
Oncology Research|August 30, 2020
Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based ChemotherapyChing-Wen Huang, Cheng-Jen Ma, Wei-Chih Su, et al.
Biomedicines|October 23, 2021
miRNA-148a Enhances the Treatment Response of Patients with Rectal Cancer to Chemoradiation and Promotes Apoptosis by Directly Targeting <i>c-Met</i>Chun-Ming Huang, Ming-Yii Huang, Yen-Cheng Chen, et al.
Frontiers in Oncology|April 1, 2022
Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort StudyHon-Yi Shi, Yen-Cheng Chen, Ching-Wen Huang, et al.
Pageof 20

Showing results (141-150 of 193) with videos related to

Sort By:
Pageof 20
International Journal of Clinical and Experimental Pathology|May 15, 2015
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patientsHsiang-Lin Tsai, Chih-Hung Lin, Ching-Wen Huang, et al.
Cancer Management and Research|May 2, 2022
Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to <i>UGT1A1</i> Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-OnlyChing-Chun Li, Tsung-Kun Chang, Yen-Cheng Chen, et al.
International Journal of Colorectal Disease|October 25, 2024
Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasisYen-Cheng Chen, Tsung-Kun Chang, Wei-Chih Su, et al.
Nanomedicine (London, England)|April 21, 2025
Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancerChing-Wen Huang, Huang-Ming Hu, Wen-Hung Hsu, et al.
Asian Journal of Surgery|February 24, 2021
Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancerPo-Jung Chen, Wei-Chih Su, Tsung-Kun Chang, et al.
Journal of Agricultural and Food Chemistry|June 4, 2021
Correlations between Urinary Monoethylhexyl Phthalate Concentration in Healthy Individuals, Individuals with Colorectal Adenomas, and Individuals with Colorectal CancerWei-Chih Su, Yi-Chen Tsai, Tsung-Kun Chang, et al.
Oncology Letters|September 23, 2020
ERCC overexpression associated with a poor response of cT4b colorectal cancer with FOLFOX-based neoadjuvant concurrent chemoradiationMing-Yii Huang, Hsin-Hua Lee, Ching-Wen Huang, et al.
Oncology Research|August 30, 2020
Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based ChemotherapyChing-Wen Huang, Cheng-Jen Ma, Wei-Chih Su, et al.
Biomedicines|October 23, 2021
miRNA-148a Enhances the Treatment Response of Patients with Rectal Cancer to Chemoradiation and Promotes Apoptosis by Directly Targeting <i>c-Met</i>Chun-Ming Huang, Ming-Yii Huang, Yen-Cheng Chen, et al.
Frontiers in Oncology|April 1, 2022
Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort StudyHon-Yi Shi, Yen-Cheng Chen, Ching-Wen Huang, et al.
Pageof 20